Table of Content

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Breast Cancer Liquid Biopsy Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product Services
6.1 Reagent Kits
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Instruments
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Services
6.3.1 Market Trends
6.3.2 Market Forecast

7 Market Breakup by Circulating Biomarker
7.1 Circulating Tumor Cells (CTCs)
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Cell-Free DNA (cfDNA)
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Extracellular Vesicles (EVs)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast

8 Market Breakup by End User
8.1 Reference Laboratories
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Hospitals and Physician Laboratories
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast

10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Biocept Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.2 Bio-Rad Laboratories Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 F. Hoffmann-La Roche AG
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Fluxion Biosciences Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Guardant Health Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Illumina Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Menarini Silicon Biosystems (The Menarini Group)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 NeoGenomics Laboratories Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Qiagen
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Sysmex Europe SE (Sysmex Corporation)
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio